Relapse is Accepted as Inevitable
Two-thirds of adults (67%) and a similar proportion of doctors (65%) believe opioid dependence can be cured, and the vast majority of adults (92%) and doctors (98%) say the disease is treatable. Yet only about two-thirds of adults (35%) and nearly one-quarter of doctors (21%) agree a stay at a rehabilitation clinic is very effective, and more than half of adults (56%) and over two-thirds of doctors (69%) believe the vast majority of people living with opioid dependence will experience a relapse.
Nearly three-quarters of adults (71%) and an even greater proportion of doctors (85%) agree people living with addiction do not seek help because they believe they can stop on their own. However, the majority of adults (83%) and an even greater proportion of doctors (92%) agree people recovering from opioid dependence need a long-term combination of medication and behavioral changes to be successful with treatment. Nearly three-in-five adults (58%) and even more doctors (73%) strongly support the use of prescription medication to treat opioid dependence. Yet only about four-in-ten adults (44%) are aware obtaining prescription medication from a doctor is a treatment option.
"The survey sheds light on barriers beyond the commonly perceived lack of patient recognition of the disease and motivation to seek treatment. As a pioneer in office-based treatment for opioid dependence, Reckitt Benckiser Pharmaceuticals is committed to doing everything we can to raise awareness about this disease and help reduce the misperceptions, stigma and stereotypes surrounding it," said Rich
SOURCE Reckitt Benckiser Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
2. Array BioPharma Announces Proposed Public Offering of Convertible Debt
3. Epizyme, Inc. Announces Pricing of Initial Public Offering
4. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
5. Swisse Wellness Australia Hires MWW As Public Relations Agency Of Record For U.S. Launch
6. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
7. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
8. PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering
9. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
10. GW Pharmaceuticals plc Announces the Closing of its Initial Public Offering on the Nasdaq Global Market
11. Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock